Appendix I: Schedule of activites

Procedures	Screening period	Concurrent chemoradiotherapy						Consolidation chemotherapy			Surgery period	Safety visit	Survival visit[5]
		D1	D7	D14	D21	D28	D35	C1/D1	C2/D1	Cn/D1	D1		
Days	-28~-1	1	7	14	21	28	35	1	22	21（n-1）+1	1	Every 30 days	Every 90 days
Time window (days)	NA	+3	+3	+3	+3	+3	+3	±3	±3	±3	±7 days	±7 days	±7 days
General Research Process													
Written informed consent[1]	√												
Inclusion/exclusion criteria	√												
Demographics/past medical history/past treatment history for lung cancer	√												
Vital sign	√	√						√	√	√	√		

Weight/height^2	√	√						√	√	√	√	
Full physical examination	√	√						√	√	√	√	
ECOG score	√	√						√	√	√	√	
12-lead electrocardiogram	√							√	√	√	√	
Laboratory assessment												
Routine blood test	√	√	√	√	√	√	√	√	√	√		
Blood biochemistry (glucose, amylase, electrolytes, etc.)	√	√	√	√	√	√	√	√	√	√		
Urine routine	√							√	√	√		
Coagulation function	√	√	√	√	√	√	√	√	√	√		
Pregnancy test	√											
Thyroid function	√							√	√	√		
Myocardial Enzyme Profile	√							√	√			
Security Monitoring and Survival												

Adverse event assessment	√	√	√	√	√	√		√	√	√	√		
State of survival													√
Assessment of efficacy													
Tumour imaging evaluation	√							√		√			
Pathological assessment											√		
Cumulative dose of RT													
		√	√	√	√	√	√						
Biomarker Exploration													
Archived/fresh tumour tissue[3]	√										√		
Full blood examination[4]		√	√	√	√	√		√	√	√	√		
Faeces[4]	√	√	√	√	√	√		√	√	√	√		

[1]Signing of the ICF should precede any programme-specified operations

[2]Height measurements were taken only during the screening period; subjects' weights were measured before each dose

[3]Subjects will be required to provide at least 5-15 sections of archived or fresh tumour tissue specimens that meet the assay requirements during the screening period; if clinically feasible, a biopsy will be requested if disease progression is detected; biomarker testing is exploratory, and patients may be enrolled if they are unable to provide a specimen that meets the requirements

[4]Subjects will be required to provide 10 ml of whole blood and stool specimens for completion of tumour biomarker testing at the following time points: prior to the first dose of drug, prior to each imaging evaluation during the treatment period and before starting the next treatment, and upon confirmation of disease progression.

Biomarker testing is exploratory and patients may be enrolled if they are unable to provide a compliant specimen.

[5]Survival follow-up: Every 90 days (±7 days) after the safety visit, with the possibility of receiving a telephone visit